治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展

doi:10.19803/j.1672-8629.20230470

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (4): 469-472.
DOI: 10.19803/j.1672-8629.20230470

治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展

顾晓彤¹, 孙雪林², 郑丽^1,*

¹中国航天科工集团七三一医院药学部,北京 100074;
²北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京 100730

收稿日期:2023-08-03 出版日期:2024-04-15 发布日期:2024-04-18
通讯作者: ^*郑丽,女,博士,主管药师,循证医学与医学信息学。E-mail: zhenglis1270755@163.com
作者简介:顾晓彤,女,硕士,药师,抗感染合理用药。
基金资助:
中央高水平医院临床科研业务费资助项目（NO.BJ-2023-200）; 国家重点研发计划（2020YFC2009000、2020YFC2009001）

Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis

GU Xiaotong¹, SUN Xuelin², ZHENG Li^1,*

¹Department of Pharmacy, Hospital 731, China Aerospace Science & Industry Corporation, Beijing 100074, China;
² Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Received:2023-08-03 Online:2024-04-15 Published:2024-04-18

摘要/Abstract

摘要： 全球真菌感染日益严重,成为人类最难控制的疾病之一,造成巨大公共卫生负担。以念珠菌为主的真菌病原体可引起严重的侵入性和全身性疾病,甚至导致死亡。2023年3月22日,美国食品药品监督管理局（FDA）批准新型棘白菌素抗真菌药物rezafungin上市,用于治疗念珠菌血症与侵袭性念珠菌病,临床研究显示本品疗效较好且安全性高。本文就其药理作用、临床评价、安全性及用法用量等进行概述。

关键词: 棘白菌素, rezafungin, 念珠菌血症, 侵袭性念珠菌感染, 药理作用, 临床评价, 安全性

Abstract: Rising global fungal infections represent a significant public health burden, which are among the most difficult diseases to manage in humans. Candida spp, a major aetiologic agent of fungal infections, can cause severe invasive and systemic diseases that can even be deadly. On March 22, 2023, the FDA approved a novel echinocandin antifungal rezafungin to treat candidemia and invasive candidiasis. Clinical studies have shown that rezafungin has a good efficacy and safety for candidiasis infections. This review describes its pharmacological action, clinical evaluation, safety, usage and dosage.

Key words: echinocandin, rezafungin, candidemia, invasive candidiasis, pharmacological effects, clinical evaluation, safety

中图分类号:

R994.11
R978

顾晓彤, 孙雪林, 郑丽. 治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展[J]. 中国药物警戒, 2024, 21(4): 469-472.

GU Xiaotong, SUN Xuelin, ZHENG Li. Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 469-472.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230470

https://www.zgywjj.com/CN/Y2024/V21/I4/469

参考文献

[1] VITIELLO A, FERRARA F, BOCCELLINO M, et al.Antifungal drug resistance: an emergent health threat[J]. Biomedicines, 2023, 11(4): 1063.
[2] BARANTSEVICH N, BARANTSEVICH E.Diagnosis and treatment of invasive candidiasis[J]. Antibiotics, 2022, 11(6): 718.
[3] FIORITI S, BRESCINI L, PALLOTTA F, et al.Antifungal combinations against candida species: from bench to bedside[J]. Journal of Fungi, 2022, 8(10): 1077.
[4] BILAL H, SHAFIQ M, HOU B, et al.Distribution and antifungal susceptibility pattern of candida species from mainland China: a systematic analysis[J]. Virulence, 2022, 13(1): 1573-1589.
[5] RODRÍGUEZ-CASTAÑO GP, ROSENAU F, STÄNDKER L, et al. Antimicrobial peptides: avant-garde antifungal agents to fight against medically important candida species[J]. Pharmaceutics, 2023, 15(3): 789.
[6] WHO. WHO fungal priority pathogens list to guide research, development and public health action[R]. WHO, 2022.
[7] HU X, YANG P, CHAI C, et al.Structural and mechanistic insights into fungal β-1, 3-glucan synthase FKS1[J]. Nature, 2023, 616(7955): 190-198.
[8] MROCZYŃSKA M, BRILLOWSKA-DĄBROWSKA A. Review on current status of echinocandins use[J]. Antibiotics, 2020, 9(5): 227.
[9] ZHANG SQ, CHENG DY.Research progress in echinocandin antifungal drugs[J]. Medical Recapitulate(医学综述), 2020, 26(5): 986-990.
[10] TANG L, QIAN Q, HU N, et al.Progress in population pharmacokinetic study of echinocandin antifungal drugs intransplant recipients[J]. Clinical Medication Journal(临床药物治疗杂志), 2023, 21(2): 17-21.
[11] FAN X, GUO LN, YANG Y, et al.Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections[J]. Chinese Journal of Mycology(中国真菌学杂志), 2020, 15(1): 10-14.
[12] LI S, DAI LB, YAO HT, et al.Meta-analysis of the efficacy and safety of echinocandins as antifungal agents in the prevention of invasive candidiasis[J]. China Pharmacy(中国药房), 2020, 31(1): 104-109.
[13] ZENG Y, GUAN ZM, HUANG TT.Cure rate of echinocandins versus non-echinocandins in the treatment of invasive candidosis infection and candidemia: Meta-analysis[J]. China Pharmacy(中国药房), 2014, 25(32): 3038-3041.
[14] TIAN C, SHI Q, WANG XL.The efficacy and safety of echinocandins to invasive candidiasis in pediatric patients: a systematic review and meta-analysis[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2019, 54(8): 659-664.
[15] SYED YY.Rezafungin: first approval[J]. Drugs, 2023, 83(9): 833-840.
[16] GARCIA-EFFRON G.Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins[J]. Journal of Fungi, 2020, 6(4): 262.
[17] ZHAO Y, PERLIN DS.Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data[J]. Journal of Fungi, 2020, 6(4): 192.
[18] HOENIGL M, SPRUTE R, EGGER M, et al.The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin[J]. Drugs, 2021, 81(15): 1703-1729.
[19] FDA. REZZAYO[EB/OB]. (2023-03-23)[2023-06-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf.
[20] THOMPSON GR, SORIANO A, SKOUTELIS A, et al.Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial[J]. Clinical Infectious Diseases, 2021, 73(11): e3647-e3655.
[21] THOMPSON III G, SORIANO A, CORNELY O.ReSTORE: efficacy and safety results of the phase 3, noninferiority trial of rezafungin in the treatment of candidemia and/or invasive candidiasis (IC)[C]. ECCMID, 2022.
[22] FLANAGAN S, WALKER H, ONG V, et al.Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations[J]. Microbiology Spectrum, 2023, 11(3): e0133923.
[23] LOGAN A, WOLFE A, WILLIAMSON JC.Antifungal resistance and the role of new therapeutic agents[J]. Current Infectious Disease Reports, 2022, 24(9): 105-116.

治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展

Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[2]	刘毅, 覃玲, 郭贤辉, 陈华, 裴宇盛. 热重和差示扫描量热分析技术在药物分析中的应用进展[J]. 中国药物警戒, 2024, 21(3): 283-289.
[3]	张孝明, 吕萍, 胡馨月, 丁晓丽, 李晶, 梁成罡. 酶联免疫法测定甘精胰岛素中单链前体残留研究[J]. 中国药物警戒, 2024, 21(3): 290-294.
[4]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[5]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[6]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[7]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[8]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[9]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[10]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[11]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[12]	刘倩, 胡晶, 李博, 杨小静. 荆花胃康胶丸联合四联疗法治疗幽门螺旋杆菌相关性胃炎的系统评价及Meta分析[J]. 中国药物警戒, 2023, 20(9): 1039-1045.
[13]	于洪礼, 于冬梅, 肖爱丽, 朱兰, 宋海波. 清开灵口服制剂安全性风险分析[J]. 中国药物警戒, 2023, 20(9): 1046-1048.
[14]	李婧, 徐烨, 刘冉佳, 潘晨, 崔向丽. 新型冠状病毒感染患者使用托珠单抗后发生不良反应的病例分析[J]. 中国药物警戒, 2023, 20(9): 1049-1053.
[15]	地力乎马·地力木拉提, 石伟, 王伽伯, 高源. 基于毒/效记载演变探讨补骨脂的安全应用研究进展[J]. 中国药物警戒, 2023, 20(8): 939-945.